GlassScriptPhysician profile
Gurkan Taviloglu
NPI 1811919889
$950.50
in general payments reported to CMS, 2019-2025
14 companies · $182 in 2025
The $182 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2020: $58.86 · 2021: $41.67 · 2022: $84.52 · 2023: $67.00 · 2024: $131 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $380.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $218.86 | 2019-2024 | |
| Amgen INC. | $172.08 | 2019-2025 | Repatha, Repatha |
| Philips North America LLC | $163.47 | 2020-2025 | (Ck4) Mcot, Event, Diagnostic Ecg Service |
| Abbott Laboratories | $145.23 | 2019-2025 | Triclip |
| Cvrx, INC. | $79.17 | 2024-2025 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $40.66 | 2022-2023 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.45 | 2022 | |
| Boston Scientific Corporation | $19.48 | 2025 | Watchman Flx |
| Sanofi-Aventis U.S. LLC | $17.34 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $16.97 | 2023 | Inpefa |
| E.R. Squibb & Sons, L.L.C. | $15.20 | 2024 | Eliquis |
| Gilead Sciences, INC. | $14.53 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.73 | 2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $13.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gurkan Taviloglu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.